Nexgel (NXGL) EBIAT (2018 - 2025)
Nexgel (NXGL) has disclosed EBIAT for 8 consecutive years, with -$647000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT rose 14.3% year-over-year to -$647000.0, compared with a TTM value of -$2.6 million through Sep 2025, up 31.34%, and an annual FY2024 reading of -$3.3 million, down 3.93% over the prior year.
- EBIAT was -$647000.0 for Q3 2025 at Nexgel, down from -$640000.0 in the prior quarter.
- Across five years, EBIAT topped out at -$550000.0 in Q3 2023 and bottomed at -$1.8 million in Q1 2022.
- Average EBIAT over 5 years is -$918894.7, with a median of -$807000.0 recorded in 2023.
- Peak annual rise in EBIAT hit 60.46% in 2022, while the deepest fall reached 160.8% in 2022.
- Year by year, EBIAT stood at -$1.6 million in 2021, then surged by 60.46% to -$648000.0 in 2022, then crashed by 78.7% to -$1.2 million in 2023, then soared by 44.56% to -$642000.0 in 2024, then dropped by 0.78% to -$647000.0 in 2025.
- Business Quant data shows EBIAT for NXGL at -$647000.0 in Q3 2025, -$640000.0 in Q2 2025, and -$678000.0 in Q1 2025.